Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,901–2,000 of 2,053
Abdalla, S. A. M., Mohammed, H. O. A., Omer, E. O. E., Ahmed, I. O. I., Ahmed, W. A. O., Ginawi, K. O. T., Abdelfattah, R. E. M., Yousif, A. A. Z., & Ismail, K. I. A. (2026) · Cureus · doi:10.7759/cureus.111723
“…which now recommend GLP-1 RAs with proven cardiovascular benefit for patients with T2DM and established or high risk of atherosclerotic disease [9], a position reaffirmed in the most contemporary guidance, including the American Diabetes Association Standards of Care in Diabetes 2025 [10] and…”
Li, X., Muthukumar, R., & Thepwongsa, I. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351307
“Among these, cardiovascular disease remains the leading cause of morbidity and mortality in patients with T2DM [6–9].”
França, D. C. H., Barbosa, A. C., Ribeiro, E. B., Neto, A. M. D. M., França, E. C. H., Borges, M. D., de Marchi, P. G. F., Honório‐França, A. C., & França, E. L. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070674
“There is growing concern regarding therapeutic approaches for treating diabetic patients due to the potential progression of the disease with various clinical complications [47].”
Yang, J., Xie, F., Zhu, X., & Zhou, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1839268
“Eligibility criteria required participants to be: (1) aged 18 years or older, and (2) diagnosed with T2DM according to American Diabetes Association standards (28).”
Unintended Consequences: The Intersection of Diabetes Technology and Disordered Eating Risk
Clinton, A., & Burroughs, B. T. (2026) · ADCES in Practice · doi:10.1177/2633559x261440142
Genitourinary Infections in Diabetes: Understanding Risk and Guiding the Diabetes Care Team
Burroughs, B. T. (2026) · ADCES in Practice · doi:10.1177/2633559x261420293
Im, S., Lee, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070826
“Given that T2DM is associated with long-term complications, including cardiovascular and renal diseases, and that lifestyle modification alone is often insufficient to achieve durable glycemic and metabolic control, there remains a strong clinical need for effective pharmacological strategies [4,5].”
Mocan, L. P., Mihu, C. M., Constantin, A.-M., Suflețel, R. T., Paunescu, I., Ilie, T., & Şovrea, A. S. (2026) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.67.1.04
“The translational relevance of EEC biology is underscored by the clinical success of GLP-1 receptor agonists and dual GLP-1/GIP co-agonists, which directly exploit the physiological secretory functions of EECs and have reshaped the pharmacological landscape of metabolic medicine [104].”
Olivares, J. K. A., Piedra, N. J. C., & Robles, L. G. (2026) · ASCE MAGAZINE · doi:10.70577/asce.v5i3.991
Cai, J., Fu, T., & Tan, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1882272
HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia
Zhang, J., Wang, Y., Lu, Z., Yang, Y., Wang, J., Zhao, L., Li, F., Miao, M., Chen, W., Wu, S., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261462927
Marsaa, K., Stenvang, J. E., & Bagger, J. I. (2026) · Diabetology · doi:10.3390/diabetology7070130
Maia, L. F., Néri, A. K. M., Fraser, S. D., Xavier, R. M. F., Bendicho, M. T. D. N. J. F., Cerqueira, J. C., de Almeida, M. D. C. C., Carioca, A. A. F., Barreto, S., Lopes, A. A., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02234-9
“Multi-factorial care programs simultaneously addressing glycemic control, blood pressure, lipid management, and lifestyle modification have demonstrated greater effectiveness in reducing cardiovascular events than interventions targeting a single risk factor [33].”
Yang, D., Jiang, H., Meng, M., Wang, Z., Shen, W., Liu, H., Yang, H., Li, X., & Hao, Y. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/2842572 · Cited by 1
“Options often include adding further OADs, GLP-1 receptor agonists, or initiating various insulin regimens [6].”
Flabe, A. H. (2026) · Research Square · doi:10.21203/rs.3.rs-10287156/v1
Metformin and Severe Post‐ COVID ‐19 Outcomes Among Individuals With Diabetes Mellitus
Butzin-Dozier, Z., Wang, L., Ji, Y., Anzalone, A. J., Olawore, O., Hafen, R., Hurwitz, E. G., Kumar, M. N., Patel, R. C., Budhihartanto, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.64898/2026.07.06.26357398
“42,43 Therefore, DPP4i patients may be less amenable to antihyperglycemic medications or may have advanced T2DM characteristics that are not captured in the EHR.”
Self-citationVournas, G., Sarvani, A., Mavridou, M., Tentolouris, A., Doumas, M. N., Liberopoulos, E. N., Kotsa, K., & Koufakis, T. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03699-w · Cited by 2
“Although current guidelines do not advocate routine or universal use of both classes in all patients [15], clinical scenarios in which combined therapy may be appropriate are common, particularly among individuals with overlapping cardiovascular, renal, metabolic, or HF-related risk profiles [16].”
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Moore, J. R., Chicano, M. T. R., Cuenca, A. M. C., & Esteban-Flores, A. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.07.005
Nutrition Counselling in Patients with Diabetes in Germany—Results from an Online Survey
Holzapfel, C., Schemmer, M., Meyer, J., & Hauner, H. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2881-7638
Demidov, N. A. D., Demidova, T. Y., & Antsiferov, M. B. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-2-03
Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes
Chuang, C., Kor, C., Wang, S. C., & Hsu, Y. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2696636
“To better understand the efficacy and safety of SGLT2 inhibitors in the elderly population, additional clinical data are needed [10–12].”
Juhi, A., Kumari, R., Mondal, H., Choudhary, P., & Sharma, S. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261463558
Medeiros, R., & Mendes, I. (2026) · Cureus · doi:10.7759/cureus.112724
“In patients with T2D and established atherosclerotic cardiovascular disease (ASCVD) or multiple cardiovascular risk factors, the American Diabetes Association recommends this dual therapy when HbA1c goals are not achieved with either SGLT2i or GLP-1 RA alone [15].”
Emoto, R., Ishii, K., Takamura, T., & Matsui, S. (2026) · Statistics in Medicine · doi:10.1002/sim.70651
Kalanin, P. M., & Uher, I. (2026) · Medicina · doi:10.3390/medicina62071367 · Cited by 2
Sleep patterns and glycemia in adults with cystic fibrosis-related diabetes: a remote pilot study
Sharma, A., Vassilakis, E., Deng, H., Salwen‐Deremer, J. K., Bartley, B. L., Putman, M. S., & Dashti, H. S. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.07.005
Brîndușe, L. A., Vicol, C., Cucu, M. A., & Bratu, E. C. (2026) · Diabetology · doi:10.3390/diabetology7070138
Chandra, G., Narang, H., & Chandy, A. (2026) · Research Journal of Pharmaceutical Dosage Forms and Technology · doi:10.52711/0975-4377.2026.00029
Alshammeri, T., Sayed, I. E., & Abdelazim, D. (2026) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2026.07.003
Pengrattanachot, N., Jaruan, O., Promsan, S., Sutthasupha, P., Jaikumkao, K., & Lungkaphin, A. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2026.159761
Andrade, F. N., Menezes-Santos, M., Goes, A. C., Santos, R. K. F., da Costa, S. S. L., dos Santos, S. H., Rocha, V. D. S., Silva, A. M. D. O. E., & Pires, L. V. (2026) · BioMetals · doi:10.1007/s10534-026-00834-6
“Unhealthy lifestyle behaviors, including physical inactivity and inadequate food consumption, are important risk factors for the development of T2DM (Davies et al. 2022).”
HbA1c Management of Endocrine Disorders and the Pharmacist's Role: Diabetes
Krass, I., Hoti, K., Khalil, H., Ludington, J. E., & Namara, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00021-8
Li, J., Dw, Z., Zhu, W., Zhang, H., Liu, C., Zhang, F., Yan, M., & Fan, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1910587
“Dietary control and regular physical activity are fundamental strategies in T2DM management (3, 4).”
Jiang, R., Wang, J., & Wang, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1883559
Violante-Ortiz, R., Gallifa, E. N., Molina, E. E. H., Fernández-Ordóñez, N., Cárdenas, J. E. G., & Reyna‐Beltrán, E. (2026) · Cureus · doi:10.7759/cureus.113266
“As beta-cell function progressively declines, many patients eventually require injectable therapy, including insulin, frequently in combination with oral antidiabetic agents [6,7].”
Semaglutide and the Heart: Focus on Their Love–Hate Relationship
Khan, E., Fernandes, J., Gohel, V., Jain, R., Jayne, W., Peck, C., Shah, T. S., Shah, R. S., LaBarge, J., Ray, S. D., et al. (2026) · Hearts · doi:10.3390/hearts7030022
“…approved for the management of type 2 diabetes mellitus (T2DM); according to current ADA/EASD guidelines, GLP-1 receptor agonists including semaglutide may be considered early in therapy, particularly in patients with obesity, established cardiovascular disease, or chronic kidney disease [1].”
Sabouret, P. F., Bernardi, M., Santos, R. D., et al. (2026) · Archives of Medical Science · doi:10.5114/aoms/226415
Frigo, F. F., Fasching, P., & Brath, H. (2026) · Nutrients · doi:10.3390/nu18162672 · Cited by 1
Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes
Mega, A., Aigner, E., Turri, C., Vittadello, F., Dauriz, M., Floreani, A., Marzi, L., Sacco, R., & Stasi, C. (2026) · Minerva Medica · doi:10.23736/s0026-4806.26.09922-2
Lee, S. K., Kim, J. K., Park, J. H., et al. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00822-5
Metformin: Emerging trends as catalyst and ligand for multifarious applications beyond diabetes
Mev, N., Chholak, A., Abedeen, M. Z., Agarwal, M., & Gupta, R. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147199
Bujdei-Tebeică, I., Stoian, A. P., Mihai, D. A., Ștefan, S., & Serafinceanu, C. (2026) · Clinics and Practice · doi:10.3390/clinpract16080141 · Cited by 1
Ponzani, P., Zilich, R., Rossi, A., Gianetto, M., Spairani, L., Candido, R., Cosmo, S. D., & Russo, G. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113467
Li, X., Zhang, Y., Wang, L., & Zhao, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1877008
“Sodium-glucose transporter 2 (SGLT2) inhibitors are a cornerstone therapy for T2DM, recommended as fi rst-line or early combination agents due to their glucose-lowering ef fi cacy and established cardio-vascular and renal bene fi ts (8, 9).”
Twardawa, P., Kubisiak, A., Matejko, B., CYRANKA, K., Lushchyk, M. L., Hajduk, J., Krzyżowska, S., Malecki, M. T., Targosz‐Korecka, M., & Klupa, T. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70613
Dizdarević-Bostandžić, A., Hadzigrahic, E., & Nišić, A. (2026) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2026-001616
Babenko, A. Y., & Игоревна, А. В. (2026) · Diabetes Mellitus · doi:10.14341/dm13474
Deka, N., Das, S., Modi, K. D., Gupta, A. D., Gupta, M., Chhabra, A., Mishra, N. K., Goroshi, M., Soneja, H., Agarwal, S., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_10_26
Malkin, S. J. P., Kandalam, S., Guareschi, G., D’Angiolella, L. S., & Hunt, B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71144
Diabetes in kidney disease progression
Caberto, S. C., Schlanger, L. E., & Fadem, S. Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34069-7.00018-5
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · Endocrines · doi:10.3390/endocrines7030040
Luo, Y., Xia, J., Yao, X., Jahed, S. A., Bee, Y. M., Chen, L., Chan, S. P., Deerochanawong, C., Alice Pik Shan, K. O. N. G., Nguyen, K. T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113474
Wu, X., Jin, M., Geng, G., Jin, Y., & Chen, J. (2026) · Healthcare · doi:10.3390/healthcare14152327
“Although the efficacy of CGM remains unclear for insulin-dependent versus non-insulin-dependent individuals, guidelines recommend CGM use for insulin-treated type 2 diabetes patients to aid in real-time identification of hypoglycemic episodes and glucose drift [115].”
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118
When HbA1c Lies: Recognizing and Managing HbA1c-Glucose Discordance in Clinical Practice.
Burroughs, B. T. (2026) · Southern medical journal (Birmingham, Ala. Print) · doi:10.14423/smj.0000000000002002
Bellido, V., Cuenca, A. M. C., Morales, C., Hazas, A. S. L. D. L., Soto-González, A., Morer-Liñan, C., Borrachero, J. M., Cuatrecasas, G., García, E. L., López‐Fernández, J., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01903-2
“Hyperglycemia, particu‑ larly postprandial, has been linked to cognitive decline and receives growing attention in guide‑ lines [49, 50].”
Muze, M., Mollay, C., Mpolya, E. A., et al. (2026) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2026.08.002
Wiater, D., Szkodziński, K., Jakubczyk, I., Maternia, J., Los, A. P. M., Majowicz-Czaszyńska, K. B., Pempuś, W., Król, N., Tomaszek, B., Blok, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5814
Metformin and Vitamin B12 Deficiency: A Prevalence Study
Laugesen, K., Abildgaard, A. M., Hoffmann, E., Madsen, L. R., Parkner, T., & Knudsen, S. T. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.001 · Cited by 1
Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia
Belančić, A., Štiglić, M. K., Fajkić, A., Jelaković, A., Pećin, I., Reiner, Ž., Jelaković, B., & Vitezić, D. (2026) · Journal of International Medical Research · doi:10.1177/03000605261470651
Seo, Y., & Woo, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167111
“Its defensible initial claim is an effect on surrogate metabolic endpoints [125,126].”
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Ma, J., & Zhen, L. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1889568 · Cited by 2
Korbolina, E. E., Gubina, M., Bryzgalov, L. O., Degtyareva, A. O., Evseenko, A., Antonseva, E. V., Korbut, A. I., Rykova, E. Y., Klimontov, V. V., Kzhyshkowska, J. G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167202
“That is why the current T2DM management strategy relies on individualization of the treatment taking into account the range of complications [8].”
Directions for improving drug provision for outpatients with diabetes mellitus
Михайлович, Л. А., & Петрухина, И. К. (2026) · Aspirantskiy Vestnik Povolzhiya · doi:10.35693/avp716110
Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies
Janež, A., Smid, T., Rizzo, M., & Tankova, T. I. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109392
Self-citationWang, T., & Shiyanbola, O. O. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01639-0
Osonoi, T., Shirabe, S., Saito, M., Hosoya, M., Douguchi, S., Ofuchi, K., & Katoh, M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16080433
“This finding suggests that the magnitude of changes after imeglimin withdrawal varied considerably among individuals, potentially reflecting interindividual differences in residual β -cell function, insulin sensitivity, or lifestyle factors [11,20].”
MEHRA, C. G., Raymond, A. M., Saboo, B., Jagadeesha, A., M., K. S., Sabharwal, M., Kumar, K., Sequeira, A., Jeny Joseline, J., & KUMAR, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1920317
“Macronutrient distribution followed a structured dietary guidance framework consistent with contemporary nutrition therapy recommendations (7, 8), which favor fl exible macronutrient ranges over fi xed prescriptive ratios.”
Grenet, G., Eskandari, R., Ko, J., Adams, S. P., Salzwedel, D. M., Heran, B. S., Ambasta, A., Bassett, K., & Thompson, W. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006225
Zhao, S., Xiong, W., Liu, F., Xia, Y., Zhang, L., & Liu, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1850534
Bastos, M. F., Longo, P. L., Furtado, G. E., dos Santos, J. R., Rodrigues, A. T., Carvalho, J. V. O., Machado‐Lima, A., Brech, G. C., Bachi, A. L. L., Barros, M. P., et al. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04076-7 · Cited by 1
Exercise and physical activity interventions in type 2 diabetes mellitus
Su, W., Li, X., Gou, H., Yuan, L., Lin, L., Lin, X., Wang, X., Xiong, Y., & Luan, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1887543
Diet in IBD: preventive and therapeutic concepts
Schwärzler, J., Tilg, H., & Adolph, T. E. (2026) · Gut · doi:10.1136/gutjnl-2025-337153
Jiang, H., Liu, J., Ying, Y., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1910565
“The effective management of T2DM depends not only on selecting appropriate treatment regimens but also on consistent, long-term patient adherence (3).”
Taybani, Z. J., Bótyik, B., Major, D., Fehértemplomi, K., Veres, A., Zatykó, M., Fazekas‐Pongor, V., Panykó, I., Kézdi, Á., Várkonyi, T. T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1906632
“However, its real-world effectiveness is limited by its burdensome use and increased risk of hypoglycaemia (26).”
InfluentialRoquemen-Echeverri, V., Escorihuela‐Altaba, C., Kushner, T., Jacobs, P. G., Garcia‐Tirado, J., & MOSQUERA-LOPEZ, C. M. (2026) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2026.08.001
Naik, B., Shrimant, Y., Patro, D., et al. (2026) · Cureus · doi:10.7759/cureus.115001
“Previous clinical and real-world studies have also demonstrated the efficacy and safety of empagliflozin-containing triple-drug regimens in patients with T2DM, supporting their use in routine clinical practice [12,13].”
Diabetes is Associated with an Increased Risk of Arthrofibrosis Following Total Knee Arthroplasty
Hall, R. P., Braithwaite, C. L., Schuyver, P. R. V., Verhey, J. T., Lebens, R. S., Deckey, D. G., Christopher, Z. K., & Bingham, J. S. (2026) · The Journal of Arthroplasty · doi:10.1016/j.arth.2026.08.041
Chen, S.-C., Huang, Y., Li, P.-Y., Chen, J.-C., Meyerowitz‐Katz, G., Yang, S., & Su, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71266
Glucose acts as a ligand for glucokinase to trigger postprandial secretion of GLP-1
Li, C., Li, M., Yang, H.-Y., Tian, X., Zhang, C., Zhao, L., Wu, J., Zhang, C., Liu, S., Yang, X., et al. (2026) · Vita · doi:10.15302/vita.2026.07.0059 · Cited by 2
Janež, A., Bojić, M., Božek, T., Kamenov, Z. A., Milenković, T., Radulian, G., & Várkonyi, T. T. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1905393
Hemoglobin A1c/Glucose Management Indicator Discordance: Our Evolving Understanding
Perlman, J. E., & Hirsch, I. B. (2026) · Clinical Chemistry · doi:10.1093/clinchem/hvag109
Saiprasad, S., & Swamy, N. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.08.005
Kageyama, M., Horii, T., Oikawa, Y., & Mihara, K. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113539
Falco, P., Flaviani, A. D., Galosi, E., Angotti, S., Stefano, G. D., Pietro, G. D., Stefano, G. D., D’Onofrio, L., Evangelisti, E., Leone, C., et al. (2026) · Pain · doi:10.1097/j.pain.0000000000004104 · Cited by 2
Smith, C. R. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000055
Ramadhani, D. S., Sulıstyanıngsıh, Y. C., Priyanto, J. A., & Umar, A. H. (2026) · ChemistrySelect · doi:10.1002/slct.74297
Turkar, M. K., Ahirwar, R., Sahu, R., Bhadane, R. N., Jain, S., & Jain, D. (2026) · ACS Omega · doi:10.1021/acsomega.5c13626
Yang, Q., Lyu, Z., Liu, M., Gao, F., meng, Y., Gong, Y., He, X., & Ge, W. (2026) · Research Square · doi:10.21203/rs.3.rs-10700011/v1
Jucha, J., Zając, D., Darasz, D., Łukawski, A., Slobozheniuk, L., Bieniak-Pentchev, M., Kaczorek, M., Machnik, K., Dziewięcka, O., & Ziębka, W. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6010
Leite, A. R., Ramalho, C., Ramos, D., Marcelino, M., Melo, M., Freitas, P., Maricoto, T., Pinto, F., do Vale, S., Calçada, E., et al. (2026) · Acta Médica Portuguesa · doi:10.20344/amp.24706
Digital Health Technologies and Hypoglycaemia
Villard, O., & Renard, É. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_24
Garg, S., Kitchen, R., Gupta, R., Donnelly, L. A., & Pearson, E. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71262
Csanalosi, M., & Kabisch, S. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02175-5
Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies
Biondi, F., Ghelardoni, S., Monti, E., Арманович, А. А., Caterina, R. D., & Madonna, R. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121898
Microvascular Diseases of the Eye: Retinal Vasculature as a Cardiometabolic Biomarker
Bessen, B. M., Weiss, M. B., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001446
Swamikkannu, D. M., Dasarapu, S., Mohan, K. D., & Shanmugam, A. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01199-7
“Incretin-based therapies, particularly GLP-1 receptor agonists, enhance insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite, leading to improved glycemic control and weight loss [77].”
A Scoping Review of Digital Behavioral Approaches to Improve Medication Adherence in Type 2 Diabetes
Huang, Y., Tiao, P.-H., & Shiyanbola, O. O. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01642-5 · Cited by 1
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.